AI Data Insight
US imports of medical, dental, and pharmaceutical products in the fourth quarter of 2025 reached a staggering $287.1 billion, representing a substantial 16.3% year-over-year increase. This robust growth is primarily driven by the explosive demand for GLP-1 weight-loss drugs and massive frontloading by pharmaceutical companies to circumvent new tariff policies. Going forward, the impact of implemented tariffs on US medical inflation and supply chain restructuring requires close monitoring.